Agreed @Deebo. My take from the Spark report is that right now PAA is valued at ~$1,00 per share (not 16 cents) AND that values MPL only for MND and canine cancer taking into account all the remaining risks through to commercialization.
The $1.00 excludes all there treatment possibilities, so why are people selling....its a ridiculously low price to sell out at......tight fists required.
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-389
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.015(6.25%) |
Mkt cap ! $109.4M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 22.5¢ | $133.9K | 573.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 303213 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 57592 | 2 |
View Market Depth
| Last trade - 15.46pm 18/10/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |